title: Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
abstract: BACKGROUND
  Organ dysfunction in AL amyloidosis is related to the production and deposition of amyloidogenic monoclonal light chains. These pathological light chains can now be quantified using the recently developed serum free light chain assay.
  
  
  METHODS
  We retrospectively reviewed 31 patients with AL amyloidosis to determine the frequency of abnormal free light chain assay results at diagnosis and whether changes in the serum free light chain assay predict outcome after therapy.
  
  
  RESULTS
  An abnormal free light chain assay was found in 30 of 31 patients (97%) at the time of diagnosis. In the subset of our patients who received treatment for AL amyloidosis, a >50% reduction of the pathological free light chain following treatment was shown to predict improved overall survival. In our series of analyses, achievement of greater magnitudes of reduction of the free light chain result did not appear to provide additional prognostic information, nor did the baseline free light chain result predict outcome.
  
  
  CONCLUSIONS
  Our findings support the use of the free light chain assay in the diagnostic work-up of patients with suspected AL amyloidosis, and also as a sensitive biomarker of response to therapy.
authors.affiliation: Department of Clinical and Laboratory Haematology, Queensland Health Pathology Service, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. kirk_morris@health.qld.gov.au
authors.forename: K L
authors.initials: KL
authors.lastname: Morris
authors.forename: J R
authors.initials: JR
authors.lastname: Tate
authors.forename: D
authors.initials: D
authors.lastname: Gill
authors.forename: G
authors.initials: G
authors.lastname: Kennedy
authors.forename: J
authors.initials: J
authors.lastname: Wellwood
authors.forename: P
authors.initials: P
authors.lastname: Marlton
authors.forename: R
authors.initials: R
authors.lastname: Bird
authors.forename: A K
authors.initials: AK
authors.lastname: Mills
authors.forename: P
authors.initials: P
authors.lastname: Mollee
mesh_terms: D000682:Amyloid / Q000097:blood*; D000686:Amyloidosis / Q000097:blood* / Q000188:drug therapy; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000682:Amyloid; D015415:Biomarkers; D007147:Immunoglobulin Light Chains; C035222:amyloid protein AL